Drugs / JL19001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07603479 | May 2026 → May 2030 expected | cancer, non-Hodgkin lymphoma | Jecho Biopharmaceuticals Co., Ltd. | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-03-17 | Jecho Biopharmaceuticals Co., Ltd. | Regulatory Jechobio JL19001 Injection Approved for Second Indication to Advance Treatment of Advanced Tumors and Lymphoma jechobio.com ↗
Recently, JL19001 Injection, an innovative drug independently developed by Jecho (Tianjin) Biopharmaceutical Co., Ltd. (hereinafter referred to as "Jecho bio"), has been officially granted the Clinical Trial Approval Notice by the National Medical Products Administration (NMPA). |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-03-17 | Jecho Biopharmaceuticals Co., Ltd. | Jechobio JL19001 Injection Approved for Second Indication to Advance Treatment of Advanced Tumors and Lymphoma jechobio.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JL19001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07603479 ↗ |
| Route | Subcutaneous | “subcutaneous injection” NCT07603479 ↗ |